Previous 10 | Next 10 |
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the 2023 National Reimbursement Drug List (NRDL) released by China’s National Healthcare Security Administration (NHSA) has been updated to include the following medicines and indications: VYVGART ® (efgarti...
2023-11-28 06:45:51 ET More on Argenx, Halozyme, etc. argenx Q3: Navigating The Highs And Hurdles Of A Market Odyssey (Rating Upgrade) Halozyme Q3: Navigating The Ups And Downs Of Its Innovative Pathway Halozyme Therapeutics, Inc. (HALO) Q3 2023 Earnings Call Transcr...
2023-11-19 11:16:04 ET Summary Zai Lab shows strong growth in oncology/autoimmune drugs; reduced losses and efficient operations evident in Q3 results. Healthy financial status with a strong current ratio of 7.68; reduced R&D expenses might signal efficiency or underinvestment...
2023-11-17 10:55:23 ET More on Zai Lab Zai Lab Stock: De-Risking Through Market Tapping Zai Lab Q3 2023 Earnings Preview Seagen, Genmab update Phase 3 data for uterine cancer therapy Seeking Alpha’s Quant Rating on Zai Lab For further details s...
2023-11-08 14:00:22 ET Zai Lab Limited (ZLAB) Q3 2023 Earnings Conference Call November 08, 2023 08:00 AM ET Company Participants Christine Chiou - Senior Vice President-Investor Relations Samantha Du - Founder, Chairperson & Chief Executive Officer Josh Smil...
2023-11-07 16:40:45 ET More on Zai Lab Zai Lab Stock: De-Risking Through Market Tapping Zai Lab Q3 2023 Earnings Preview Seagen, Genmab update Phase 3 data for uterine cancer therapy Seeking Alpha’s Quant Rating on Zai Lab Historical earnings d...
Total product revenue of $69.2 million for the third quarter of 2023, representing 22% y-o-y growth; 27% y-o-y growth at constant exchange rate (CER) VYVGART ® (efgartigimod alfa injection) achieved $4.9 million sales since its commercial launch in September in China ...
Weyco Group Inc. (WEYS) is expected to report for Q1 2024 Gladstone Land Corporation (LAND) is expected to report $0.16 for Q3 2023 PlayAGS Inc. (AGS) is expected to report $0.01 for Q3 2023 Ardmore Shipping Corporation (ASC) is expected to report $0.43 for Q3 2023 Sage Therapeuti...
Zai Lab Limited (ZLAB) is expected to report $-0.94 for Q3 2023
2023-11-06 17:35:59 ET More on Zai Lab Zai Lab Stock: De-Risking Through Market Tapping Zai Lab Limited (ZLAB) Q2 2023 Earnings Call Transcript Seagen, Genmab update Phase 3 data for uterine cancer therapy Biggest stock movers today: Trip.com, Airbnb, Blackst...
News, Short Squeeze, Breakout and More Instantly...
First and only NMPA-approved subcutaneous (SC) injectable providing additional flexibility and optionality for gMG patients in China Consistent clinical benefit and safety profile of efgartigimod SC compared to IV demonstrated in Phase 3 ADAPT-SC study Zai Lab Limited (NASDAQ: Z...
Manuscript represents the first publication from China’s gynecology oncology field to be published in Cell Publication highlights first-time learnings about the landscape of ovarian cancer microenvironment stratified by HRD and how a PARP inhibitor perturbs it Data suggest ...
2024-07-05 18:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...